We are excited to share that Chai Discovery, which builds frontier artificial intelligence to predict and reprogram the interactions between biochemical molecules , leveraged Oracle Cloud Infrastructure (OCI) to support the advanced technology needs of its breakthrough AI model, Chai-2. Recently unveiled, Chai-2 is the first AI system capable of reliably generating novel antibodies from scratch directly from target epitopes, eliminating the need for iterative laboratory screening or extensive optimization. Chai Discovery’s team brings deep experience from industry leaders and is supported by prominent investors.
Rapid, Accurate Antibody Generation at Scale
Chai-2 integrates sophisticated structural prediction with generative molecular design to produce antibodies exhibiting high specificity, favorable therapeutic profiles, and rapid experimental validation. In laboratory tests spanning approximately 50 diverse targets, Chai-2 found hits to half of the targets within two weeks when testing only 20 designs. The model also achieved a global success rate of close to 20% for antibodies. This represents a 100-fold improvement over existing approaches.
Accelerating Scientific Breakthroughs with OCI Infrastructure & Engineering
Chai Discovery chose OCI to build and scale its bare metal GPU-based supercluster required for Chai-2 because of OCI’s proven reliability, scalability, and collaborative engineering support. High-speed RDMA cluster networking enabled Chai to operate a large cluster of GPU instances with the same ultralow-latency networking and application scalability expected from on-premises environments.
“Developing Chai-2 required both technical depth and infrastructure that could scale with the pace of science,” said Jack Dent, Co-Founder and President, Chai Discovery. “We selected OCI because we needed a platform that could support rapid experimentation, large model training, and tight coordination with a responsive infrastructure engineering team.”
Chai Discovery’s breakthrough illustrates what becomes possible when cutting-edge science is paired with infrastructure and support built for AI. By enabling rapid, large-scale de novo antibody design directly from target structures, Chai Discovery is showing a path toward reducing both the time and cost of therapeutic discovery and unlocking new problems that will ultimately lead to breakthrough therapies for patients. OCI was built to support exactly this kind of high-impact, high-efficiency innovation.
Chai Discovery also announced that they are opening early access to Chai-2 to select partners.
For more information: